Open Access Open Access  Restricted Access Subscription or Fee Access

Cryptosomes: An Emerging and One of the Most Promising Drug Delivery System

Renu Anti, Mamta Kadawla, Lakshita Rao, Bimla Khati


Vesicular drug delivery systems provide a potential solution to the issues of medicines with low bioavailability and quick removal from the body. The solid-lipid particulate system, emulsion-based system, solid lipid tablet, and vesicular system are the four types of lipid-based drug delivery methods. Cryptosomes are a new vesicular drug delivery method that may address the drawbacks of traditional drug delivery systems, such as high stability, improved bioavailability, prolonged-release, and reduced elimination of quickly metabolizable medicines, among others. The term Cryptosome comes from the Greek words “Crypto”, which means concealed, and “Soma”, which means body. It is made up of distearoylphosphatidylcholine and phospholipids like distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG). Vesicular systems represent the use of vesicles as a carrier system or additive in many areas. This study examines different vesicular drug delivery systems and highlights cryptosome's progress in the field of drug delivery. Researchers working in the area of vesicular drug delivery will benefit from this review.


Vesicular system, Drug Delivery, Cryptosome, Formulation, Composition, Preparation

Full Text:



Sharma VK, Mishra DN, Sharma AK, Srivastava B. Liposomes: present prospective and future challenges. Int J Curr Pharm Res 2010;1(2):7-16.

Weiner N, Martin F, Riaz M. Liposome a drug delivery system. Drug Dev Ind Pharm 1989;15(10):1523–24.

Dinesh Kumar, Deepak Sharma, Gurmeet Singh, Mankaran Singh, Mahendra Singh Rathore. Lipoidal soft hybrid bio carriers of supramolecular construction for drug delivery. ISRN Pharm 2012;2012:474830.

Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006;1(3):297–315.

Blume G, Cevc G. Drug-carrier and stability properties of the long-lived lipid vesicles, cryptosomes, in vitro and in vivo. J Liposome Res 1992;2(3):355-68.

Blume G, Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Bio Phys Acta 1993;1146(2):157-68.

Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987;223(1):42-6.

Kanika. Recent technical advances in emerging vesicular systems. Int J Pharm Prof Res 2012;3:568-84.

Blume G, Cevc G. Circulation time of cryptosomes. Bio Chem Bio Phys Acta 1993;1146:157-68.

Ciobanu M, Heurtault B, Schultz P, Ruhlmann C, Muller CD, Frisch B. Layersome: development and optimization of stable liposomes as drug delivery system. Int J Pharm 2007;344(1-2):154-7.

Kirby C, Clarke J, Gregoriadis G. Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980;186(2):591-8.

Mayank Gangwar, Ragini Singh, RK Goel, Gopal Nath. Recent advances in various emerging vesicular systems. An overview. Asian Pac J Trop Biomed 2012;2(2):S1176-S1188.

Dipali SR, Kulkarni SB, Betageri GV. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. J Pharm Pharmacol 1996;48(11):1112-5.

Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 1973;298(4):1015-9.

Biju SS, Sushama Talegaonkar, Mishra PR, Khar RK. Vesicular system an overview. Indian J Pharm Sci 2006;68(2):141-53.

Allen TM, Hansen C, Rutledge J. Liosomes with prolonged circulation times-factors affecting uptake by reticuloendothelial cell and other tissues. Bio Chim Bio Phys Acta 1989;981(1):27-35.

Walker SA, Kennedy MT, Zasadzinski JA. Encapsulation of bilayer vesicles by self-assembly. Nature 1997;387(6628):61–4.


  • There are currently no refbacks.

Copyright (c) 2021 Research & Reviews: A Journal of Drug Formulation, Development and Production